Efficacy analysis of CAG priming regimen combined with talidomide, interferon and interleukin 2 as the induction therapy for relapsed refractory acute myeloid leukemia.
10.3760/cma.j.issn.0253-2727.2016.04.017
- Author:
Yingling ZU
;
Yanli ZHANG
;
Jian ZHOU
;
Huifang ZHAO
;
Ruirui GUI
;
Zhen LI
;
Mengjuan LI
;
Xudong WEI
;
Yongping SONG
1
Author Information
1. Department of Hematopathy, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
- Publication Type:Journal Article
- MeSH:
Aclarubicin;
therapeutic use;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Cytarabine;
therapeutic use;
Granulocyte Colony-Stimulating Factor;
therapeutic use;
Humans;
Interferons;
therapeutic use;
Interleukin-2;
therapeutic use;
Leukemia, Myeloid, Acute;
drug therapy;
Recurrence;
Remission Induction;
Thalidomide;
therapeutic use
- From:
Chinese Journal of Hematology
2016;37(4):334-336
- CountryChina
- Language:Chinese
